Clinical Trials Logo

Clinical Trial Summary

This is a study of TAK-755 in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP). The main aim of this study is to determine the percentage of participants with a clinical response without plasma exchange during the study. Participants who have an acute attack of iTTP will receive TAK-755 and immunosuppressive therapy during their stay at the hospital until they achieve a clinical response. Participants will also be treated with TAK-755 for an additional time of up to 6 weeks after the acute phase. In total, participants will stay in the study for approximately 3 months.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05714969
Study type Interventional
Source Takeda
Contact Takeda Contact
Phone +1-877-825-3327
Email medinfoUS@takeda.com
Status Recruiting
Phase Phase 2
Start date March 21, 2023
Completion date March 15, 2025

See also
  Status Clinical Trial Phase
Completed NCT03393975 - A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP) Phase 3
Withdrawn NCT05393999 - SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations Phase 2
Not yet recruiting NCT06441578 - A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
Terminated NCT00411801 - Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP) Phase 3
Completed NCT00937131 - The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP) Phase 2
Recruiting NCT04683003 - A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura Phase 3
Available NCT05770219 - Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)